The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
May 30th 2024
Take these 4 steps to help prevent health conditions and disease naturally.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Comparable Efficacy of Generic and Brand-Name Drugs for Chronic Conditions Shown in Study
March 26th 2019Although generic versions of prescription medications can be a cheaper alternative for patients, many perceive generics as less effective and less safe than their brand-name counterparts.
Read More
FDA OKs Esketamine Nasal Spray for Treatment-Resistant Depression
March 6th 2019Once Spravato is determined as an appropriate treatment option, in accordance with the REMS, the patient will be treated at a certified treatment center that is trained to administer the medicine and address patient needs.
Read More
FDA Updates Fluoroquinolone Labeling to Strengthen Mental Health, Hypoglycemia Risks
July 11th 2018Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release
Read More
FDA Issues Safety Warning for Drug That Treats Seizures, Bipolar Disorder
April 26th 2018Lamotrigine (Lamictal) for seizures and bipolar disorder can cause hemophagocytic lymphohistiocytosis (HLH), a rare, but very serious immune system reaction that excessively activates the body’s infection-fighting immune system.
Read More
FDA OKs Lurasidone for Use as Bipolar Medication in Children
March 7th 2018Officials with the FDA have approved a supplemental new drug application (sNDA) to expand the use of lurasidone HCl (Latuda, Sunovion) to include the treatment of bipolar depression in pediatric patients (10 to 17 years of age).
Read More